Novartis extends Unilife deal for drug delivery device

By Dan Stanton contact

- Last updated on GMT

Novartis extends Unilife deal for drug delivery device

Related tags: Drug delivery, Pharmacology

Novartis has extended a deal with Unilife for the supply of an injectable drug delivery system for use with an early stage drug candidate.

In November 2013​, Novartis inked a deal with drug delivery firm Unilife for a customised device – consisting of syringe, needle, tubing, controller and pump – to be used in combination with one of its early stage pipeline drugs.

The Swiss Pharma Giant told this publication it has “made an extension to the current agreement with Unilife regarding the supply of a product used with an early-stage compound,” ​but refused to name the candidate or reveal additional terms of the agreement.

The candidate is, however, being delivered to a specific organ during an ongoing clinical drug trial in order to target a high prevalence disease where no pharmacological treatments are currently available, according to Unilife.

The firm’s General Manager of Ocular and Novel Delivery Systems Rick Beckman said the partnership “continues to progress favourably," ​and Unilife "looks forward to supporting Novartis in the advancement of this therapy, which requires a high-precision delivery system to enable its accurate administration to the target organ of the human body.”

$4.3m cost savings

In related news, Unilife has revealed in an SEC filing​ it will cut operation costs by approximately $4.3m, following the implementation of a workforce reduction plan unveiled last week​.

Around 50 jobs, or 17%, of the total workforce will be lost as Unilife says it has now completed its product portfolio and is moving away from the R&D phase to a commercial outlook.

Operating expenses for the full year ending June 30 2015 were $94m, up 41% year-on-year.

Related news

Show more

Related products

show more

Q&A: Effective Drug Product Process Development

Q&A: Effective Drug Product Process Development

Catalent Pharma Solutions | 14-Jan-2021 | Insight Guide

In this Q&A, a Catalent Biologics expert shares his expertise with drug product process development challenges, risks and how to mitigate them, the...

Vaccine Innovation in the Era of COVID19

Vaccine Innovation in the Era of COVID19

Covance Patient Safety | 01-Oct-2020 | Sponsored Link

During this time of worldwide crisis, there is an increasing demand for the acceleration of a vaccination for COVID19. Regardless of the great recent advancements...

Related suppliers

Follow us


View more